These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

970 related articles for article (PubMed ID: 30106450)

  • 41. PCGF3 promotes the proliferation and migration of non-small cell lung cancer cells via the PI3K/AKT signaling pathway.
    Hu Y; Cheng Y; Jiang X; Zhang Y; Wang H; Ren H; Xu Y; Jiang J; Wang Q; Su H; Zhang B; Qiu X
    Exp Cell Res; 2021 Mar; 400(2):112496. PubMed ID: 33485844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells.
    Wang S; Takayama K; Tanaka K; Takeshita M; Nakagaki N; Ijichi K; Li H; Nakanishi Y
    J Thorac Oncol; 2013 Jun; 8(6):719-25. PubMed ID: 23625155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NDRG2 suppresses proliferation, migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells through regulating the AKT/XIAP signaling pathway.
    Yang CL; Zheng XL; Ye K; Ge H; Sun YN; Lu YF; Fan QX
    Int J Biochem Cell Biol; 2018 Jun; 99():43-51. PubMed ID: 29530788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
    Phuchareon J; McCormick F; Eisele DW; Tetsu O
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.
    Lu Y; Wang Y; Zhang M; Liu L; Li F; Zhang J; Ye M; Zhao H; Zhao J; Yan B; Yang A; Zhang R; Li X; Ren X
    Oncotarget; 2016 Apr; 7(17):23594-607. PubMed ID: 26988752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
    Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
    Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pyroptosis-related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma.
    Zhang Y; Wang Y; Weng J; Chen J; Zheng Y; Xia Y; Huang Z; Zhao L; Chen X; Tang H; Huang Y
    Mol Carcinog; 2024 Nov; 63(11):2218-2236. PubMed ID: 39136610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
    Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
    Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ZNF452 facilitates tumor proliferation and invasion via activating AKT-GSK3β signaling pathway and predicts poor prognosis of non-small cell lung cancer patients.
    Zhang X; Zhou H; Zhang Y; Cai L; Jiang G; Li A; Miao Y; Li Q; Qiu X; Wang E
    Oncotarget; 2017 Jun; 8(24):38863-38875. PubMed ID: 28418919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer.
    Zhang F; Zhang X; Meng J; Zhao Y; Liu X; Liu Y; Wang Y; Li Y; Sun Y; Wang Z; Mei Q; Zhang T
    Oncotarget; 2015 Jun; 6(18):16239-52. PubMed ID: 25938545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.
    Zhu T; An S; Choy MT; Zhou J; Wu S; Liu S; Liu B; Yao Z; Zhu X; Wu J; He Z
    J Cell Mol Med; 2019 Mar; 23(3):1852-1864. PubMed ID: 30515972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location.
    Wang G; Guo C; Zhao H; Pan Z; Zhu F; Zhang L; Wang Q
    BMC Cancer; 2018 Mar; 18(1):260. PubMed ID: 29510688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC).
    Gorgisen G; Ozes D; Pehlivanoglu S; Erdogan A; Dertsiz L; Ozbilim G; Ozbudak IH; Savas B; Ozes ON
    Exp Lung Res; 2013 Nov; 39(9):387-98. PubMed ID: 24117170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
    Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W
    Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
    Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
    Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer.
    Vázquez PF; Carlini MJ; Daroqui MC; Colombo L; Dalurzo ML; Smith DE; Grasselli J; Pallotta MG; Ehrlich M; Bal de Kier Joffé ED; Puricelli L
    Clin Exp Metastasis; 2013 Dec; 30(8):993-1007. PubMed ID: 23832740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade.
    Cho HJ; Ahn KC; Choi JY; Hwang SG; Kim WJ; Um HD; Park JK
    Int J Oncol; 2015 Mar; 46(3):1149-58. PubMed ID: 25586525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.
    Yang Y; Liu L; Zhang Y; Guan H; Wu J; Zhu X; Yuan J; Li M
    Int J Cancer; 2014 Oct; 135(7):1531-42. PubMed ID: 24550137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.